CLINICAL RESEARCH
Application of Evidence-Based Medical Therapy Is Associated With Improved Outcomes After Percutaneous Coronary Intervention and Is a Valid Quality Indicator
Wissam A. Jaber, MD,
Ryan J. Lennon, MS,
Verghese Mathew, MD,
David R. Holmes, Jr, MD,
Amir Lerman, MD and
Charanjit S. Rihal, MD, MBA*
Mayo Clinic, Rochester, Minnesota
Manuscript received March 16, 2005;
revised manuscript received June 23, 2005,
accepted June 27, 2005.
* Reprint requests and correspondence: Dr. Charanjit S. Rihal, Director, Cardiac Catheterization Laboratory, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905 (Email: rihal{at}mayo.edu).
OBJECTIVES: We sought to determine whether the prescription of evidence-based medications at discharge after successful percutaneous coronary intervention (PCI) can predict long-term clinical outcome.
BACKGROUND: The association of standard-of-care drug utilization and long-term mortality and morbidity after PCI is not well studied.
METHODS: We performed a retrospective cohort study of successful PCI procedures performed on 7,745 patients between March 1, 1998, and December 31, 2004. Discharge medications were analyzed, and a medication score (MEDS) was developed. A MEDS of 1 was assigned for each of the following medication classes: 1) antiplatelet, 2) lipid-lowering, 3) beta-blocker, and 4) angiotensin-converting enzyme (ACE) inhibitor. The outcomes measured were long-term death, myocardial infarction, and revascularization.
RESULTS: Patients with MEDS of 3 to 4 had higher-risk profiles based upon standard clinical and angiographic criteria. Despite this, at a median follow-up of 36 months, patients with a MEDS of 3 or 4 were at lower risk of death than those with a MEDS of 0 or 1 (8.9%, 7.5%, and 13% for MEDS of 4, 3, and 0 to 1, respectively; p = 0.014). After adjustment for covariates, a MEDS of 3 to 4 was associated with significantly lower mortality or myocardial infarction in follow-up than a MEDS of 0 to 1 (hazard ratios of 0.72 and 0.67 for MEDS of 3 and 4, respectively; p < 0.01). There was no association between MEDS and target vessel revascularization.
CONCLUSIONS: After successful PCI, the use of multiple evidence-based classes of cardiovascular medicationsantiplatelet, lipid-lowering, beta-blockers, and ACE inhibitorsis associated with improved outcome free of death or MI.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | CABG = coronary artery bypass graft surgery | | CHF = congestive heart failure | | CI = confidence interval | | HR = hazard ratio | | MEDS = medication score | | MI = myocardial infarction | | PCI = percutaneous coronary intervention | | TVR = target vessel revascularization |
|
This article has been cited by other articles:

|
 |

|
 |
 
B. R. Shah, M. Adams, E. D. Peterson, B. Powers, E. Z. Oddone, K. Royal, F. McCant, S. C. Grambow, J. Lindquist, and H. B. Bosworth
Secondary Prevention Risk Interventions Via Telemedicine and Tailored Patient Education (SPRITE): A Randomized Trial to Improve Postmyocardial Infarction Management
Circ Cardiovasc Qual Outcomes,
March 1, 2011;
4(2):
235 - 242.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Shafazand, A. Rosengren, G. Lappas, K. Swedberg, and M. Schaufelberger
Decreasing trends in the incidence of heart failure after acute myocardial infarction from 1993-2004: a study of 175 216 patients with a first acute myocardial infarction in Sweden
Eur J Heart Fail,
February 1, 2011;
13(2):
135 - 141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Singh, D. R. Holmes, R. J. Lennon, and C. S. Rihal
Development and Validation of Risk Adjustment Models for Long-Term Mortality and Myocardial Infarction Following Percutaneous Coronary Interventions
Circ Cardiovasc Interv,
October 1, 2010;
3(5):
423 - 430.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Johnman, K. G. Oldroyd, D. F. Mackay, R. Slack, A. C. H. Pell, A. D. Flapan, K. P. Jennings, H. Eteiba, J. Irving, and J. P. Pell
Percutaneous Coronary Intervention in the Elderly: Changes in Case-Mix and Periprocedural Outcomes in 31 758 Patients Treated Between 2000 and 2007
Circ Cardiovasc Interv,
August 1, 2010;
3(4):
341 - 345.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Lancefield, D. J. Clark, N. Andrianopoulos, A. L. Brennan, C. M. Reid, J. Johns, M. Freeman, K. Charter, S. J. Duffy, A. E. Ajani, et al.
Is There an Obesity Paradox After Percutaneous Coronary Intervention in the Contemporary Era?: An Analysis From a Multicenter Australian Registry
J. Am. Coll. Cardiol. Intv.,
June 1, 2010;
3(6):
660 - 668.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Venkitachalam, K. E. Kip, S. R. Mulukutla, F. Selzer, W. Laskey, J. Slater, H. A. Cohen, R. L. Wilensky, D. O. Williams, O. C. Marroquin, et al.
Temporal Trends in Patient-Reported Angina at 1 Year After Percutaneous Coronary Revascularization in the Stent Era: A Report From the National Heart, Lung, and Blood Institute-Sponsored 1997-2006 Dynamic Registry
Circ Cardiovasc Qual Outcomes,
November 1, 2009;
2(6):
607 - 615.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Shafazand, M. Schaufelberger, G. Lappas, K. Swedberg, and A. Rosengren
Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry
Eur. Heart J.,
March 2, 2009;
30(6):
671 - 678.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Venkitachalam, K. E. Kip, F. Selzer, R. L. Wilensky, J. Slater, S. R. Mulukutla, O. C. Marroquin, P. C. Block, D. O. Williams, S. F. Kelsey, et al.
Twenty-Year Evolution of Percutaneous Coronary Intervention and Its Impact on Clinical Outcomes: A Report From the National Heart, Lung, and Blood Institute-Sponsored, Multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries
Circ Cardiovasc Interv,
February 1, 2009;
2(1):
6 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Singh, E. D. Peterson, M. T. Roe, F.-S. Ou, J. A. Spertus, J. S. Rumsfeld, H. V. Anderson, L. W. Klein, K. K.L. Ho, and D. R. Holmes
Trends in the Association Between Age and In-Hospital Mortality After Percutaneous Coronary Intervention: National Cardiovascular Data Registry Experience
Circ Cardiovasc Interv,
February 1, 2009;
2(1):
20 - 26.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Singh, C. S. Rihal, B. J. Gersh, V. L. Roger, M. R. Bell, R. J. Lennon, A. Lerman, and D. R. Holmes Jr
Mortality Differences Between Men and Women After Percutaneous Coronary Interventions: A 25-Year, Single-Center Experience
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2313 - 2320.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Cassar, T. I. Morgenthaler, R. J. Lennon, C. S. Rihal, and A. Lerman
Treatment of Obstructive Sleep Apnea Is Associated With Decreased Cardiac Death After Percutaneous Coronary Intervention
J. Am. Coll. Cardiol.,
October 2, 2007;
50(14):
1310 - 1314.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Singh, C. S. Rihal, B. J. Gersh, R. J. Lennon, A. Prasad, P. Sorajja, R. E. Gullerud, and D. R. Holmes Jr
Twenty-Five-Year Trends in In-Hospital and Long-Term Outcome After Percutaneous Coronary Intervention: A Single-Institution Experience
Circulation,
June 5, 2007;
115(22):
2835 - 2841.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Prasad, C. S. Rihal, R. J. Lennon, H. J. Wiste, M. Singh, and D. R. Holmes Jr
Trends in Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusions: A 25-Year Experience From the Mayo Clinic
J. Am. Coll. Cardiol.,
April 17, 2007;
49(15):
1611 - 1618.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Goyal, J. H. Alexander, G. E. Hafley, S. H. Graham, R. H. Mehta, M. J. Mack, R. K. Wolf, L. H. Cohn, N. T. Kouchoukos, R. A. Harrington, et al.
Outcomes Associated With the Use of Secondary Prevention Medications After Coronary Artery Bypass Graft Surgery
Ann. Thorac. Surg.,
March 1, 2007;
83(3):
993 - 1001.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|